BioSpace News Archive

DURECT Corporation announced that it will report its second quarter 2021 financial results and host a conference call after the market close on Thursday, July 29, 2021.

Parexel, a leading global clinical research organization (CRO) focused on development and delivery of innovative new therapies to advance patient health, today announced a strategic partnership with Beijing Illness Challenge Foundation (ICF) in China.

Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world’s largest pure-play in vitro diagnostics companies, today announced its VITROS® Immunodiagnostic Products IL-6 Reagent Pack, the latest addition to Ortho’s VITROS® Critical Care menu, is now available in EU Countries, U.K. and several ASPAC and LATAM countries.*

GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that clinicians have treated the first patient in a Phase 1b/2 study evaluating the company’s lead drug candidate, uproleselan, added to cladribine plus low dose cytarabine (LDAC) in patients with treated secondary AML (ts-AML).

Lixte Biotechnology Holdings, Inc commented on pre-clinical research demonstrating that inhibition of protein phosphatase 2A (PP2A) with LB-100 combined with the experimental drug, vosoritide (BioMarin), was even more effective than vosorotide alone in stimulating bone length and cartilage area.

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has added to its suite of intellectual property protection after being awarded a patent from the Republic of Korea’s Intellectual Property Office for the Company’s CoPrimer™ technology.

The emergence and spread of antimicrobial resistance have been identified as a significant problem for human health that profoundly impacts clinical outcomes and healthcare-associated costs.

According to The Insight Partners market research titled ‘Colorectal Cancer to 2027 – Global Analysis and Forecasts by Modality, and End User’.

The Ventilator market was valued at US$ 2,620.45 million in 2019and is projected to reach US$ 8,239.18 million by 2027; it is expected to grow at a CAGR of 12.9% from 2020to 2027.

The home diagnostics for urinary tract infection market was valued at US$ 847.85 million in 2019 and is expected reach US$ 1,354.02 million by 2027; it is projected to grow at a CAGR of 6.2% from 2020 to 2027.